Search

Displaying results 1041 - 1050 of 4575 in total
  1. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  2. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth musc...

  3. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet,...

  4. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

    Mixtures: Vista Advanced AREDS2 Formula
  5. Drug

    Davanat

    go.drugbank.com/drugs/DB15311
    Investigational

    Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).

  6. Drug

    Dotinurad

    go.drugbank.com/drugs/DB16145
    Investigational

    Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).

  7. Drug

    Timolol

    go.drugbank.com/drugs/DB00373
    ApprovedInvestigational

    [L6727] Timolol was first approved by the FDA in 1978. … [L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

    Mixtures: DORZOCOMP VISI 20+5MG/ML, DORZOCOMP VISI 20+5MG/ML
  8. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    However, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect.

  9. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64040,L64041] It is taken by mouth once daily. … [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test.

  10. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    [T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]